Egyptian Board Infectious Diseases - independent subject foundations cheat sheet

Separate specimen quality, organism identification and susceptibility evidence.

A drug protected from one enzyme may remain vulnerable to another.

Exposure, site and patient factors affect the meaning of susceptibility.

Use structured allergy assessment and reassess route, spectrum and duration.

Distinguish surveillance definitions from clinical infection assessment.

Positive urine or molecular stool tests do not independently prove symptomatic disease.

Severity and fulminant complications require different actual findings.

Evaluate device need, source control and system effects as well as the antibiotic.

Match empirical treatment with severity, source, host and resistance context.

A major diagnostic criterion is not the complete diagnosis by itself.

Source control and organ support can be as urgent as drug selection.

Use scores and biomarkers as contributions rather than unconditional instructions.

Match immune mechanism, duration and preventive treatment to the differential.

PJP, toxoplasma and MAC prophylaxis are not interchangeable threshold rules.

CNS opportunistic disease can change ART timing.

Coordinate infection treatment and immunosuppression decisions rather than apply a timeline mechanically.

Distinguish mycobacterial infection, active disease and resistance categories.

Interpret travel-related fever through location, timing and actual severity.

Separate blood-stage malaria treatment from eligible liver-stage radical cure.

Use organism, host and regional context rather than universal travel prescriptions.